F-fluorodeoxyglucose (
18 F-FDG) and the radiolabeled somatostatin analog 68 Ga-DOTATATE were performed to make clear diagnosis of oncogenic hypophosphatemic osteomalacia. Both of the examinations revealed a suspicious mass in subcutaneous tissue around the umbilicus and enlarged right axillary lymph nodes [ Figure 1A and 1B].
The patient was subjected to surgery for resection of the subcutaneous mass and enlarged right axillary lymph nodes after obtaining written informed consent. The subcutaneous mass was red, round-shaped without necrosis. It displayed spindle-shaped cells with oval nuclear and eosinophilic cytoplasm, and characteristic scattered cloud-like calcium deposits under histologic examination. No atypical cells, abnormal mitotic activity, or necrosis were observed [ Figure 1C ]. On the basis of its morphologic and immunohistochemical features, the tumor was diagnosed as a phosphaturic mesenchymal tumor. Interestingly, histologic examination of lymph nodes revealed immunoglobulin G (IgG) 4-positive plasma cells >100 cells per high-power field, and the IgG4-positive rate was up to 70% of IgG-positive plasma cells in intrafollicular zones [ Figure 1D ]. Supplemental laboratory testing demonstrated elevated IgG4/IgG ratio, thus an IgG4 lymph node disease could be diagnosed.
The patient was released from the hospital after a rapid recovery of serum phosphorous [ Figure 1E ] and urinary phosphorus loss. He reported normal serum phosphorous and significantly improved symptoms during our one and a half months follow-up.
Tumor-induced osteomalacia (TIO) is a rarely seen tumorrelated disease with characteristics of hypophosphatemia and abnormal urinary phosphate wasting. The increased level of fibroblast growth factor 23 (FGF23), a circulating phosphaturic hormone produced by tumors leads to decreased renal phosphate reabsorption through reduction of the sodium-phosphate co-transporter expression in the proximal renal tubule. Clinically, patients suffering from TIO may develop weakness, fatigue, bone, muscle pain, and fractures.
Tumors resulting in TIO are often too small to localize by conventional radiologic methods. In the case that anatomical imaging (CT or magnetic resonance imaging) fail to detect the tumors, scintigraphy with a radiolabeled somatostatin analog ( 111 indium octreotide scintigraphy or 68 Ga-DOTATATE PET/CT) with or without 18 F-FDG PET/CT is recommended. Selective venous sampling with FGF23 should be taken into consideration when other tests come to nothing.
IgG4-related diseases (IgG4-RD) is a fibro-inflammatory condition involving multiple organs characterized by storiform fibrosis, increased serum IgG4 level, and inflammatory infiltrate with IgG4-rich plasma cells. It was reported that patients with IgG4-RD had higher risks of solid and hematologic malignancies than the general population. [1, 2] Furthermore, history of malignancy may be related to subsequent IgG4-RD development. [3] However, the connection between IgG4-RD and malignancy still remains unclear. Some studies claimed no connection between IgG4-RD and malignancy. A Japanese prospective study found that the incidence of total malignancies in IgG4-RD patients was similar to that in the general population. [4] Pathogenesis of IgG4-RD and TIO are totally different as immunity-related and FGF-23 related.
We speculate that there is no association between TIO and IgG4-RD in this patient.
Here, we presented a 60-year-old man who had suffered from severe clinical manifestations of TIO due to a mesenchymal tumor in the umbilicus and was discovered an IgG4 lymph node disease accidentally. In this case, the tumor was identified by 68 Ga-DOTATATE PET/CT and surgical removal of the tumor resulted in significant relief of symptoms and hypophosphoremia. When meeting with unexplained bone pain and fatigue, TIO should always be taken into consideration and scintigraphy with a radiolabeled somatostatin analog should be applied early when routine examination failed to detect tumors.
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